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Abstract: The castor plant (Ricinus communis L.) has been known since time immemorial in traditional
medicine in the pharmacopeia of Mediterranean and eastern ancient cultures. Moreover, it is still
used in folk medicine worldwide. Castor bean has been mainly recommended as anti-inflammatory,
anthelmintic, anti-bacterial, laxative, abortifacient, for wounds, ulcers, and many other indications.
Many cases of human intoxication occurred accidentally or voluntarily with the ingestion of castor
seeds or derivatives. Ricinus toxicity depends on several molecules, among them the most important
is ricin, a protein belonging to the family of ribosome-inactivating proteins. Ricin is the most studied
of this category of proteins and it is also known to the general public, having been used for several
biocrimes. This manuscript intends to give the reader an overview of ricin, focusing on the historical
path to the current knowledge on this protein. The main steps of ricin research are here reported,
with particular regard to its enzymatic activity, structure, and cytotoxicity. Moreover, we discuss ricin
toxicity for animals and humans, as well as the relation between bioterrorism and ricin and its impact
on environmental toxicity. Ricin has also been used to develop immunotoxins for the elimination
of unwanted cells, mainly cancer cells; some of these immunoconjugates gave promising results in
clinical trials but also showed critical limitation.
Keywords: bioterrorism; cancer therapy; castor bean; folk medicine; immunotoxins; plant toxins;
ribosome-inactivating proteins; ricin; rRNA N-glycosylase activity; traditional medicine
Key Contribution: Despite the large number of papers on ricin, it is often difficult for inexpert readers
to have a global view on this toxin. This manuscript intends to give an overview of ricin. Starting
from the use of Ricinus plant in traditional and folk medicine, we highlight the milestones of research
on ricin, with particular regard to its enzymatic activity, structure, cytotoxicity, toxicity for animals
and humans and the double face of its employ, for biocrimes and medicine.
1. Castor Bean in Traditional and Folk Medicine
Ricin derives from Ricinus communis L. (Euphorbiaceae family), also known as castor bean or
palma Christi. The genus Ricinus has only one known species: the castor oil plant. The plant possibly
originates from Africa and Asia and now is widespread throughout temperate, subtropical, and tropical
areas, growing as an invasive plant or being cultivated for different purposes.
The castor plant has been known since time immemorial and its use in the prehistoric era has been
evidenced by archaeological findings such as that of the Border Cave in South Africa. Traces of wax
containing ricinoleic and ricinelaidic acids were found on a thin wooden stick, which was suggested to
be a poison applicator, dating back to about 24,000 years ago [1]. The castor seeds and other parts of
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the castor plant were certainly utilized in ancient Egypt for pharmacological purposes. In the Ebers
Papyrus, an Egyptian medical treatise dating back to before 1500 BCE, an entire chapter is dedicated to
the castor bean that is indicated as an abortifacient, a laxative, a remedy for abscessual illness, baldness,
and so on [2]. In the Hearst Papyrus, written approximately in the same period, various castor plant
parts are included as ingredients in some prescriptions for internal use, with the aim of expelling fluid
accumulation or promoting diuresis, as well as for external use as poultices for bandaging [3]. Ancient
Egyptians knew the toxicity of castor bean and the use of seed pulp, included in drug preparations
for oral ingestion, was recommended only in small amounts. In addition, a castor seed-containing
concoction was prescribed to cure the urinary disease of a possibly diabetic child [4]. Around 400 BCE,
the father of western medicine Hippocrates prescribed castor bean oil for laxative and detoxifying
action [5]. The Greek herbalist and physician Pedanius Dioscorides (40 to 90 CE) in De Materia Medica
wrote that castor seeds could be used as expectorant, diuretic, emetic, laxative, anti-inflammatory, to
cure erysipelas, burns, varicose veins, etc. [6]. In the same period, Pliny the Elder (23 to 79 CE) wrote
Naturalis historia, comprising the whole area of antique knowledge. In this encyclopedic work, also
castor bean found a place [7].
Castor bean was used also in the pharmacopeia of eastern ancient cultures. In Chinese traditional
medicine, castor seeds were recommended for their anthelmintic activity; seed poultice and leaf juice
were prescribed for external use to treat ulcers and chronic wounds, whereas the latex was instilled
in the ear for rhinitis treatment (reviewed in [8]). In Ayurveda, castor plant is used for rheumatic
conditions, as well as for gastropathy, constipation, inflammation, fever, ascites, bronchitis, cough,
skin diseases, colic, and lumbago. In Yunani medicine, castor root is used as a purgative and for skin
diseases, the leaves are used to increase breastmilk production and are applied to skin for burns, the
seeds and the oil act as a purgative, useful in liver troubles, pains, lumbago, boils, piles, ringworm,
inflammation, ascites, asthma, rheumatism, dropsy, and amenorrhea (reviewed in [9]). Ground castor
seeds or leaf paste have been applied in veterinary medicine to heal sprains, swelling, and wounds [10].
Castor bean has been used in folk medicine throughout the world and has been reported: (i) As a
galactogogue on the Mediterranean coasts of Europe, where fresh leaves or leaf juice are applied on
the puerperal breast to promote lactation; (ii) as a remedy for various articular, cutaneous, or ocular
diseases in Africa, where crushed seeds or oil, sometimes in combination with other plants, are spread
or rubbed on the part of the body in need, or a root decoction is drunk to induce uterine contraction
as an abortive; (iii) as a medicament to cure erysipelas, flu, inflammation of the womb, and stomach
aches in the Caribbean, where a leaf poultice is recommended; (iv) as an anthelmintic or a purgative in
Brazil where the seed oil is orally consumed, or locally applied with the purpose of stopping hair loss,
healing wounds, or burns (reviewed in [11]).
The laxative and abortifacient activities of castor seeds have been attributed to the activation
of intestinal and uterine smooth-muscle cells via prostaglandin EP3 receptors induced by ricinoleic
acid [12]. Castor oil-induced diarrhea can be antagonized by hexane extract of Citrus limon peel
that activates antisecretory and antimotility mechanisms through the β adrenergic system [13]. The
purgative and anthelmintic actions of the oral ingestion of castor seeds, at least in part, have been
ascribed to the irritating effect caused to the intestine by ricin, as reported in toxicological studies
(reviewed in [14]). In addition, the antiflogistic action of castor bean could be related to the high
toxicity of ricin to macrophagic cells, which are responsible for producing inflammatory cytokines
(reviewed in [15]). This effect, together with the anti-pathogen activity of ricin, could promote healing
of the lesions, thus justifying its use in the treatment of various skin conditions.
2. The Ricin Story
Castor seed toxicity began to be investigated at the end of nineteenth century at Schmiedeberg’s
laboratory in Strasbourg. The toxic component of Ricinus could be extracted with water and precipitated
with alcohol, but it lost its toxic activity through heating, treatment with strong acid, or repeated
precipitation with alcohol. In 1887, Dixson supposed that the toxicity of Ricinus was due to an
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albumen-like toxic body [16]. However, it was still unknown whether the seed toxicity was due to a
protein or a glycoside (reviewed in [17]). The problem was solved at the Medical Faculty of Dorpat
(now Tartu) where an extremely toxic protein was partially purified from castor seed or press cake and
named ricin. This finding was published in the doctoral thesis written by Hermann Stillmark under
the supervision of Prof. Rudolf Kobert [18]. Stillmark noticed the agglutinating activity of ricin on red
blood cells, that had mistakenly been believed to be the cause of ricin toxicity until the agglutinin was
separated from the toxin [19].
Paul Ehrlich began his experiments in immunology by feeding mice with small amounts of ricin
or abrin, another similar plant toxin, until they were accustomed and became resistant to the toxin
used, yet still remaining sensitive to the other toxin. The immunization was strictly specific, started
after a few days, and persisted at least for several months [20,21]. He was successful in the production
of antisera against abrin and ricin and in the determination of antibody titer in serum and milk. Ehrlich
drew animal experiments that clarified the transmission of passive immunity from mother to offspring
through the transplacental transfer of antibodies and through breastfeeding. He investigated the
dynamics of the antibody response and was the first to envisage the presence of binding sites on the cell
surface (reviewed in [22]). These studies, together with those on the immunity to bacterial toxins, led
him to formulate his side-chain theory of antibody formation and to win, in 1908, the Nobel Prize [23].
Figure 1. The main milestones of ricin research.
Interest in ricin was rekindled when the anticancer activity of this toxin on Ehrlich ascites cells in
a mouse model was published [24]. A strong inhibition of protein synthesis by ricin was observed
in cultures of both Ehrlich ascites tumour cells and Yoshida ascites hepatoma cells. The inhibition of
protein synthesis by ricin requires more time in rat liver than in neoplastic cells [25]. The prospect of a
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possible use in cancer therapy highlighted the need to investigate which part of the proteosynthetic
machinery was damaged and how the toxin managed to enter the cell to reach its target. Hereinafter, we
highlight the milestones of research on ricin, with particular regard to its enzymatic activity, structure,
cytotoxicity, toxicity for animals and humans, and its use as an immunotoxin, used in experimental
models and in clinical trials. The main milestones are shown in Figure 1.
2.1. Ricin Structure
The first information about the bi-chain nature of ricin structure dates to the early 1970s, when
it was shown that ricin was composed of two chains, A (active) and B (binding), linked together
through a disulphide bond [26,27]. In the same period, the complete primary sequence of the ricin A
and B chains was determined [28,29]. Ricin holotoxin structure was solved for the first time at 2.8 Å
resolution (Figure 1) [30]. This pioneering work demonstrated that ricin A chain was a globular protein
folded into three domains all contributing to the active site, while the B chain lectin folded into two
domains, each binding lactose in a shallow cleft. The interface between the A and B chains showed
some hydrophobic contact in which proline and phenylalanine side chains played a prominent role.
Four years later, the same researchers refined ricin structure at 2.5 Å (Figure 2a), allowing a more
detailed molecular description of the holotoxin and of the separated A and B chains [31–33]. Ricin
A chain has been described as a globular protein consisting of 267 amino acids and organized in 8
α-helices and 8 β-strand structures. Ricin B chain consists of 262 amino acids and two homologues
domains, each containing a lactose binding site and several areas of amino acid homology, possibly
derived from a gene duplication. In 1995, after purification of a complex of ricin A chain cross-linked to
the ribosome, it was found the binding of ricin A chain with the ribosomal proteins L9 and L10e [34,35].
Figure 2. (a) Ribbon model of the crystal structure of ricin at 2.5 Å (accession number Protein Data
Bank 2AAI). The A chain domains are colored in green, blue, and light blue; the B chain domains
are colored in yellow and orange. (b) Catalytic site of ricin. The key residues are indicated and
colored in blue, whereas adenine substrate is depicted in red. (c) Proposed mechanism of depurination
reaction catalyzed by ricin. The hydrolysis proceeds through a dissociative mechanism forming an
oxocarbenium transition state. Arg180 protonates the leaving group and the N-glycosidic bond is
broken. Glu177 deprotonates the hydrolytic water (highlighted by a red dotted rectangle) that attacks
carbon to complete the depurination reaction. Figure 2a and 2b were produced by PyMOL (version
2.3.1); Figure 2c was produced by ACD/ChemSketch (version 2015.2.5).
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The knowledge of the tridimensional structure of ricin yielded more information on its active site.
Studies based on the formation of complexes between the A chain, both native and recombinant, and
adenine-containing nucleotides allowed for the identification of key residues in enzymatic activity. In
particular, Tyr80, Tyr123, Glu177, Arg180, and Trp211 were found to form the binding site for adenine
(Figure 2b) [30,36]. In the 1990s, the molecular mechanism of adenine release was hypothesized:
Adenine is sandwiched between Tyr80 and Tyr123 in a pi stacking interaction; the N3 of adenine is
protonated by Arg180, promoting the C1’-N9 bond breaking, and thus forming an oxocarbenium
moiety on the ribose (Figure 2c) [36,37]. This transition state is stabilized by Glu177; a water molecule
lies on the opposite side of the sugar ring from adenosine, which will be polarized by Arg180 to a
hydroxide character that rapidly attacks the sugar carbon completing the reaction.
2.2. Ricin Enzymatic Activity
The introduction of a cell-free system utilizing a lysate from rabbit reticulocytes [38] helped to
clarify that ricin inhibited the peptide chain elongation (Figure 1) [27]. The two polypeptides showed
different properties: The A chain possessed the toxic activity, while the B chain was a galactose-specific
lectin binding the cell surface [26]. Treating the toxin with reducing agents resulted in more activity in
inhibiting cell-free protein synthesis [39]. Firstly, the target of the toxic action was identified as the
ribosome (Figure 1), then as the 60 S subunit of eukaryotic ribosome [40], which became unreactive
toward elongation factors [41]. The toxin was found to prevent the binding between elongation
factors and ribosomes avoiding the subsequent elongation-factor-dependent GTPase activity [41,42].
The A-chain molecule was very active on its substrate and it was calculated that one molecule can
inactivate 2000 ribosomes/min, with a Km of 0.1–0.2 mM [43].
In addition to ricin, several other plant proteins have been identified to possess a similar protein
synthesis inhibiting action. Most of them had a single polypeptide chain similar to the A chain of ricin.
They were called Ribosome-Inactivating Proteins (RIPs) (reviewed in [44,45]).
The already supposed enzymatic nature of ricin A chain was finally demonstrated in 1987 by
Endo et al. who discovered that ricin A-chain cleaved the N-glycosidic bond of an adenine residue,
A4324 in rat 28 S RNA, from the ribose of a highly conserved ribosomal RNA single-stranded loop
involved in the binding of elongation factors (Figure 1). The toxin did not directly break the RNA
chain, but the depurinated RNA was susceptible to hydrolysis [46,47]. Consequently, ricin activity was
identified as an rRNA N-glycosidase (EC 3.2.2.22).
Following this, it was demonstrated that the enzymatic activity of RIPs was broader than previously
described. All tested RIPs were able to release adenine from DNA, in addition to rRNA, and some
of them were also able to act on other polynucleotide substrates, releasing adenine from the sugar
phosphate backbone of polynucleotide substrates (Figure 1) [48,49]. For this reason, the name of
adenine polynucleotide glycosylase was proposed for RIPs. Thus, the ability of acting on various
substrates and extensively depurinating some of them, suggested that the protein synthesis inhibition
could be only one of the ways of RIP-mediated cell killing. Ricin was shown to be able to release
adenine from rRNA, DNA (chromatin and naked), and also poly(ADP-ribosyl)ated poly(ADP-ribose)
polymerase, an enzyme involved in DNA repair [48,50]. Furthermore, it was observed that many
RIPs were able to cleave more than one adenine: ricin was able to detach few adenines from the DNA
(tens), but some single-chain RIPs were able to detach even thousands of them. The hypothesis that
ricin could act directly on DNA in cellular models was strengthened by the evidence that damage to
nuclear DNA, consistent with the enzymatic activity (adenine release) on DNA in cell-free systems,
was concomitant with protein synthesis inhibition and preceded apoptosis [51].
2.3. Ricin Cellular Uptake, Routing, and Toxicity
Starting from the mid-1970s, several research groups focused on ricin binding and internalization
studies, demonstrating that the interaction of ricin with the cell started from the binding of the B chain
to galactosyl residues on the cell surface, allowing access to the endosomal compartment [52]. Ricin
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binds to both glycolipids and glycoproteins with terminal galactose. Since ricin binds to a variety of
different molecules, it seems to be internalized by different endocytic pathways, as well as by using
different pathways to reach the Golgi apparatus to intoxicate the cell. In HeLa cells, about 107 binding
sites were found for ricin, but only small amount of the bound toxin reached the Golgi network and
participated in cell intoxication [52].
Firstly, it was reported that ricin entered into cytoplasm through clathrin-dependent
endocytosis [53]. Afterwards, it became clear that clathrin-independent mechanisms were also
involved [54]. After cell uptake, ricin is delivered to early endosomes, from where most of protein
molecules are recycled back to the cell surface or delivered, via late endosomes, to lysosomes for
proteolytical degradation. A small amount of non-degraded ricin is addressed within the trans-Golgi
network [55]. The involvement of the Golgi complex in ricin routing was confirmed using different
Golgi-disrupting agents, such as brefeldin A, monensin, etc. In fact, the pretreatment with these agents
inhibited the cytotoxic effects of ricin [56]. It was demonstrated that ricin was cycled from Golgi to
the endoplasmic reticulum via coatomer protein 1 (COP-1)-coated vesicles [57], although it was later
proved that the COP-1-independent pathway could also be involved [58].
The complete elucidation of intracellular ricin traffic occurred when it was demonstrated that,
after reaching the endoplasmic reticulum, the two ricin chains were separated, and the A chain
was retro-translocated through the quality control pathway delivering misfolded proteins to cytosol
(Figure 1) [59]. Recently, it has been demonstrated that cholesterol rafts are required for Golgi transport
of ricin; meaning that glycosphingolipids may not be required (reviewed in [60]).
The portion of A chain that quickly refolded, thus avoiding ubiquitination and proteosomal
degradation, was able to reach its intracellular target (reviewed in [61]). It was estimated that one
molecule of active ricin that arrives to its substrate is enough to kill one cell [62].
The discovery that ricin, and some related toxins, may be retrogradely transported along neuronal
processes (Figure 1) [63] opened a new field of research in neurobiology and this property has been
exploited for the selective destruction of neuron bodies.
Different cell types have shown variable levels of sensitivity to ricin (reviewed in [14]), possibly
because of the mannose receptor expression on the cell surface and endocytosis efficacy. Ricin has
been shown to be one of the most toxic plant toxins on cell lines with IC50s (concentration inhibiting
protein synthesis by 50%) ranging from less than 0.1 to 1 pM [26,64–66]. However, it must be taken into
account that it is very difficult to make a direct comparison of the data available in the literature about
ricin cytotoxicity, because of the differences in the experimental approaches and technical conditions.
The polynucleotide depurinating activity of RIPs suggests the possibility of a wider toxic action
on many biological substrates, not excluding the induction of oxidative stress. This could explain the
induction of more than one cell death pathway, e.g. apoptosis and necroptosis, caused by ricin and
other RIPs (Figure 1) [64,67].
3. Ricin Toxicity in Humans and Animals
On one hand, ricin has been studied for bio-medical applications, exploiting the ability of the
A-chain to kill target cells once linked to a monoclonal antibody, as below described in the immunotoxins
chapter. On the other hand, ricin has attracted nefarious interests, with a history of military, criminal,
and terroristic uses [68].
The acute toxicity of ricin is highly variable depending on the animal species and strain.
The pathological effects and subsequent clinical signs of ricin intoxication depend also on the route of
exposure, as this dictates the subsequent tissue distribution of the toxin. Following intravenous or
intramuscular administration, lesions eventually develop in the spleen, liver, and kidney whilst the
lung remains unaffected. After oral ingestion, the gastrointestinal tract is severely affected. Inhalational
exposure produces effects that are mainly confined to the respiratory tract [69].
The majority of data on animal toxicity has been derived from laboratory experiments in rodents,
principally rat and mouse models. Oral administration of ricin was reported to give a lethal dose (LD)
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for 50% of animals (LD50s) 20 to 30 mg/kg in rat and 15 to 35 mg/kg in mouse [70–72]. For intravenous,
inhalation and intraperitoneal routes, toxicity is approximately 1000-fold higher than that obtained for
the oral route, with LD50 values in mouse of 2 to 10 µg/kg, 3–5 µg/kg and 22 µg/kg, respectively [70,73].
The lower toxicity of ricin after oral exposure is due to the protein destruction in the lumen of the
intestinal tract [74,75]. Ricin acts in a time- and concentration-dependent manner. Notably, there is a
time delay of about 10 h before death occurs, even when very high doses are applied [76].
3.1. Oral Toxicity
In humans, most intoxications occurred accidentally or voluntarily with the ingestion of castor
seeds; only a few cases of intentional absorption of castor bean extracts have been documented in
suicide attempts [76]. Whole-ingested beans can pass intact through the gastrointestinal tract, whereas
chewing facilitates ricin release. Also, it has been reported that the seed can act as ‘timed-release’
capsule for the toxin, allowing its release in the lower bowel, where it causes more damage [72]. After
ingestion, vomiting, diarrhea, and abdominal pain are common symptoms. Massive gastrointestinal
fluid and electrolyte loss are described, often complicated by hematemesis or melaena. Finally,
hypovolemic shock and multiorgan failure occur, which particularly involves the spleen, liver, and
kidney [77,78].
Despite the high number of intoxicated subjects with castor beans, it is quite difficult to calculate
LD values for ricin in humans. In fact, the effective ingested ricin dose can only be supposed, because
of ricin content variations depending on the size, weight, and moisture of the seeds, as well as on
cultivar, region, season, and plant growth stage. Moreover, in intoxicated subjects, it must be taken
into account the degree of mastication, stomach content, age, and comorbidities, parameters that are
obviously more heterogeneous compared to experimental poisoning of animals. Considering all these
parameters, the fatal oral dose of ricin in humans has been estimated to range from 1 to 20 mg/kg
(approximately 5 to 10 beans) [70,79].
3.2. Inhalation Toxicity
No data are available for human ricin uptake by inhalation. In non-human primates, LD50 has
been estimated to be 5 to 15 µg/kg depending on aerosol particle size. Inhalation of particles that are
able to penetrate deeply into the lungs (1 to 5 µm diameter) display much more toxicity than larger
particles [72,80]. Inhalation of ricin causes slow onset of respiratory distress (difficulty breathing),
coughing, fever, pulmonary lesions, and edema. Intoxicated animals develop fibrinopurulent
necrotizing pneumonia accompanied by necrotizing lymphadenitis, typically after a dose-dependent
delay of 8 to 24 h. Death occurs as a result of respiratory failure due to massive alveolar fluid
accumulation. The liver, kidney, and small intestines appear congested, although little histologic
changes have been shown [72,80,81].
3.3. Parenteral Toxicity
Data regarding parenteral ricin intoxication derive mainly from animal studies. By injection, mice
had an LD50 of 3 to 5 µg/kg by intravenous and 22 µg/kg by subcutaneous route [82], rabbits had LD50
0.5 µg/kg by the intravenous route and 0.1 µg/kg by the intramuscular route, while guinea pigs had
LD50 <1.1 µg/kg by the intravenous route and 0.8 µg/kg by the intramuscular route [83]. Human data
only derives from the few cases of suicide or murder, or their attempt; the most known episode is the
assassination of the Bulgarian dissident Georgi Markov, who in 1978 died three days after possibly
being stabbed with an umbrella loaded with a ricin-containing pellet (Figure 1) [84].
By parenteral administration, immediate local pain at the injection site is reported, followed by
general weakness within five hours. The following symptoms, that are general and maybe similar
to sepsis (fever, headache, dizziness, anorexia, nausea, vomiting, hypotension, abdominal pain), can
be delayed for as much as 10 to 12 h, even with high doses. Usually local tissue damage at the
site of the injection is observed. Laboratory abnormalities included elevated liver transaminases,
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amylase and creatinine kinase, hyperbilirubinemia, myoglobinuria, and renal impairment. The clinical
course may progress to multisystem organ failure. Preterminal complications included gastrointestinal
hemorrhage, hypovolemic shock, and renal insufficiency [78,84].
4. Bioterrorism and Environmental Toxicity
Ricin is currently monitored as Schedule 1A of the Chemical Weapons Convention (CWC) and is
a Category B substance under the Biological and Toxins Weapons Convention (BTWC) [80]. Despite
its toxicity, ricin is less potent than other agents, such as botulinum neurotoxin or anthrax. It has
been estimated that eight tons of ricin would have to be aerosolized over a 100 km2 area to achieve
about 50% casualty, whereas only a kilogram of anthrax spores would cause the same effect [85]. Thus,
deploying an agent such as ricin over a wide area, although possible, becomes impractical from a
logistics standpoint. However, the availability of castor beans and the quite simple procedure for
rough ricin purification have attracted criminal and terrorist interest for small scale biocrimes or to
cause collective media-driven alarm [80].
From castor seeds, a nontoxic oil can be extracted that has multitude of uses in many sectors,
including cosmetic, pharmaceutic, mechanical, and chemical industry. Castor oil production is
increasing worldwide because of its versatile application, low cost, availability, and biodegradability.
In addition, the oil-free seed pulp can be used in agriculture as a natural fertilizer [86], although the
processing of castor seeds requires great caution due to the high allergenicity [87,88] and extreme
toxicity [76] of their protein fraction, represented, above all, by ricin. World production of castor
oil increased from 0.8 million tons in 2000 [89] to 1.21 million tons in 2014 [90], with a castor seed
production of 1.49 million tons in 2017 [91]. Leading producing countries are India, with over 80% of
the global yield, Mozambique, China, Brazil, Myanmar, Ethiopia, Paraguay, and Vietnam [92]. The oil
makes up about 50% of the weight of the seeds and is mostly constituted of ricinoleic acid (90%), with
minor amounts of dihydroxystearic, linoleic, oleic, and stearic acids. Ricin isoforms and the alkaloid
ricinine, are not transferred to the oil fraction during extraction, which can be performed by cold or
warm pressing, but remain in the seed cake [93,94].
Castor bean meal press cake or other residues of the castor oil production have been employed as
a protein source for feed or fertilizer, but their use is very limited due to ricin toxicity [76]. In 2008,
the European Food Safety Agency defined ricin as an undesirable substance in animal feed. Ricinus
derived material should be appropriately inactivated through physical and/or chemical methods to
guarantee animal and human health [95]. Nevertheless, many accidental poisonings are still reported
for animals eating improperly detoxified fertilizer or other agricultural products containing castor
derived material [76,94].
In order to block the toxic action of ricin, different strategies have been evaluated: Vaccines,
inhibitors, and passive immunity. Vaccines against ricin with the consequent production of neutralizing
antibodies did not give satisfactory results in vivo (reviewed in [96]). Inhibitors of ricin can block
the active site or work as a substrate analogue; however, the available data are limited to in vitro
experiments [97]. More recently, inhibitors of cell routing have been developed, sometimes giving
promising results, also in vivo [98,99]. To date, passive immunity has proven to be the only effective
strategy for treating intoxication caused by ricin. The delay in the appearance of signs of intoxication
makes confirmation of exposure, diagnosis of intoxication, and the subsequent medical response
technically and logistically challenging. The development of anti-ricin sera or antibodies, effective
even when used several hours after toxin exposure, represents a step forward in treatment of ricin
intoxication, as it increases the time window of intervention (WOO, window of opportunity). Many
authors described effective post-exposure treatment of ricin intoxication with specific antibodies, but
with a limited WOO (~8 h) [100–103]. Other authors reported a survival between 50% and 89% of mice
treated with anti-sera 24 h after intoxication [104–106]. Once internalized into the cells, ricin cannot be
neutralized by antibodies, thus limiting the therapeutic window. However, Whitfield et al. in 2017
reported 100% protection in aerosolized ricin-treated mice with a single administration of a F(ab’)2
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polyclonal ovine antitoxin given 24 h post-exposure [69]. Even when performed in the same animal
species, comparison between diverse experiments is often difficult, due to the different toxin dose and
route of administration utilized. Moreover, there are few data about correlation between the antitoxin
dose required for protection and the WOO.
5. Ricin-Containing Immunotoxins
Many researchers have tried to exploit the high cytotoxicity of ricin for medical purposes to
eliminate pathological cells. Although ricin possesses highly efficient cell killing mechanisms, it lacks
selectivity towards cell targets. In order to increase selectivity, the possibility of linking ricin to carriers
specific for targets on unwanted cells has been explored. The most widely used carriers are antibodies
and the corresponding conjugates are referred to as immunotoxins (ITs).
The first IT, created in 1976 by Moolten and co-workers, was made by Ricin Toxin-A chain (RTA)
linked to a rat tumor-specific antibody against a rat lymphoma, namely (C58NT)D (Figure 1) [107].
To date, a multitude of pre-clinical and clinical studies have shown the potential use of several
ricin-ITs towards different cancer types, from hematological to solid ones, and towards normal cells,
unwanted due to them being responsible for a pathological state (reviewed in [108,109]). Different
approaches have been used, over time, to generate ITs. In the first strategy, ITs were composed by
the antibody chemically linked to the entire RIP and they were used for in vitro studies showing
high cytotoxicity [110]. Despite the high in vitro efficiency, the relevant non-specific toxicity reported
in vivo, due to the characteristics of the lectin chain, brought researchers to sterically block, chemically
modify, or remove the B chain, thus balancing toxicity and specificity. In 1985, Weil-Hillman et al.
tested an anti-Mr 67,000 protein linked to either blocked-chain B ricin or RTA, reporting interesting
results in vitro, but not in vivo in a nude mouse model [111]. The 1980s were years of great ferment for
molecular biology and genetic engineering, paving the way for the second generation of ITs. Many
researchers tried to improve the IT penetration in tumor mass by reducing the antibody size, using
antigen-binding (Fab), or variable (Fv) fragments instead of entire antibodies. In 1988, Ghetie et
al. created a new IT composed by Fab conjugated to chemically deglycosylated RTA (dgA) [112].
A few years later, they used an anti-CD122-dgA IT in SCID-Daudi mice, showing promising results
since the IT was able to specifically kill tumor cells in vivo, extending the mean survival time up to
57.9 +/− 3.8 days [113]. Moreover, FitzGerald et al. described the antitumor activity of recombinant
RTA (rRTA) linked to anti-mouse transferrin receptor in a nude mouse model of human ovarian
cancer. Animals treated with IT had an extended life span from 45 (lower doses) to 70/80 days
(higher doses) [114]. Finally, in 1997 the first ricin-containing recombinant immunotoxin (rIT) was
obtained through the expression of a fusion gene composed by sequences encoding anti-CD19-FVS191
(single-chain Fv), cathepsin D proteinase digestion site, and rRTA. In this work, the authors compared
the cytotoxicity of the rIT with the chemical linked IT, evidencing that only the latter was toxic in
target cells [115]. About 20 ricin-ITs have been tested in Phase I, II, and III clinical trials to treat
patients with tumors, either hematological or solid, transplant rejection, and GvHD. The first Phase I
clinical trial, giving promising results, was conducted by Spitler et al. in 1987 (Figure 1), by treating 22
metastatic malignant melanoma patients with an IT composed by murine monoclonal anti-melanoma
antibody coupled to RTA (XOMAZYME-MEL) [116–118]. Additionally, ITs were also exploited for the
treatment of autoimmune diseases. Indeed, anti-CD5/RTA was the first IT used in clinical trials for
therapy of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and
insulin-dependent diabetes mellitus [119,120]. The advantages and limitations of ricin containing ITs
for cancer therapy were recently discussed together with strategies for reducing the immunogenicity
of recombinant ITs [121,122].
A different new approach consists of nanoparticle construction, in which ricin is genetically fused
to carrier peptides that are able not only to recognize specific cellular target, but also to auto assemble,
as stable nanoparticles, thus increasing the toxin-concentration into the targeted site [109,123,124].
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6. Conclusions
In conclusion, ricin is a highly cytotoxic plant protein and has been of great utility to develop
a number of anti-cancer immunotoxins. Ricin, and of some other RIPs, are able to act on multiple
molecular targets inside the cell, thus triggering different death pathways; this makes such proteins
more attractive for cancer treatment than conventional chemotherapy, in which one of the major
problems is the rise of resistant cells [67,125]. However, ricin-containing ITs have also been shown
to exhibit many limitations, such as unspecific toxicity, organ toxicity (mainly liver, kidney, and
vasculature), immunogenicity, fast removal from blood stream, and lysosomal degradation inside cells.
As a result, despite of the significant efforts made over the past few years, ricin as therapeutic agent
has not achieved much impact at the clinical level. The challenge is still open, and frontline research is
directed towards recombinant immunotoxins and nanocarriers, or towards other novel techniques
such as the vector-driven expression of active plant toxin genes in tumor cells [109,126].
Although ricin is not toxic enough to hypothesize a use over a wide area for terrorist purposes,
the availability of castor beans and the quite simple procedure for rough ricin purification have
stimulated the interest of criminals and terrorists for small-scale biocrimes. This justifies researchers’
efforts to obtain faster and more sensitive ricin detection tests. Furthermore, the study of inhibiting or
neutralizing molecules and the timing of clinical events following ricin intoxication could lead to the
definition of one or more validated therapies.
Finally, the use of castor bean derivatives should be carefully monitored because of the potential
presence of active ricin. In fact, the large use of these products in agriculture, without an effective
ricin inactivation, has already caused several cases of animal intoxication, and can be hazardous for
human health.
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